AzTrials
AzTrials

Cardiometabolic Health IndicatorsNCT07125001

Mango Intake and Gut and Cardiometabolic Health in Hispanic/Latino Adolescents

A study testing Ataulfo mango in people with Cardiometabolic Health Indicators and Vascular Function in Healthy Volunteers, run by University of California, Davis at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Mangos contain a number of nutrients that may improve gut and metabolic health. The purpose of this research is to see how eating mangos every day for 4 weeks instead of snacks high in calories and low in nutrients such as cookies, crackers, chips, and candy can impact adolescent health. Read more about this study

Who is it for?
Ages 12 to 19 yearsHealthy volunteers can take part
What is being tested?
Ataulfo mango
Could I receive a placebo?
No, everyone receives an active treatment
How many people
25 participants
Where
1 siteUnited States
Study dates
1 Oct 2025to 31 Mar 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 19 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • - Male or Female 12-19 years old
  • BMI ≥ 85th percentile (https://www.bcm.edu/bodycomplab/BMIapp/BMI-calculator-kids.html)
  • Self-reported Hispanic/Latino
  • Subject is willing and able to comply with the study protocols
  • Subject is willing to consume the test products
  • Female-specific criteria: if menstruating, eumenorrheic (regular monthly menstrual cycles of 25-30-days in length)
  • Access to a smartphone or tablet at least 1x / day and willing to take pictures associated with the products to be consumed in the study

Who cannot join

  • - Reported food allergies.
  • Currently taking prescription drugs, with the exception of asthma inhalers, which are allowed
  • BMI <85th percentile (https://www.bcm.edu/bodycomplab/BMIapp/BMI-calculator-kids.html)
  • Current participation in a moderate or high-intensity daily exercise routine
  • Self-reported disease, serious illness, or who are currently under acute medical care.
  • Currently taking prescription drugs.
Show all 12Show fewer
  • Any supplement use, including multi-vitamin/ mineral, herbal, plant or botanical, fish oil, and oil supplements, and not willing to discontinue before starting the study.
  • Vegetarian or vegan diet
  • Self-reported malabsorption or gastrointestinal issues
  • Fruit and vegetable intake exceeding daily recommendations of 5 servings
  • Smoking (vaping, conventional nicotine-containing products or marijuana)
  • Current enrollee in a clinical research study

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Roberta R Holt, PhD contact

15304005952

rrholt@ucdavis.edu

Genesis G Guerra Gaitan, MS contact

gguerragaitan@ucdavis.edu

United States1 site, 1 recruiting
  • Academic Surge; Ragle Human Nutrition Research Center

    Davis, California, 95616

    Roberta R Associate Researcher, PhD, 530-400-5952

    California, 530-400-5952

    Recruiting

Other trials in United States

About this study

Official title: The Influence of Mango-Derived Intestinal Microbial Metabolites on Gut Permeability, Inflammation, and Cardiometabolic Health Markers in Hispanic/Latino Adolescents

Mangos contain a number of nutrients that may improve gut and metabolic health. The purpose of this research is to see how eating mangos every day for 4 weeks instead of snacks high in calories and low in nutrients such as cookies, crackers, chips, and candy can impact adolescent health.

Read the detailed description

This study will record the functional and metabolic effects of daily mango intake, incorporated into the habitual diets of Hispanic/Latino adolescent children. This racial group is considered the most significant minority in the US, accounting for 19.1% of the population. The proposed study design allows for comparing baseline metabolic and physiological function to the real-world situation of adding a new snack food to a child in the major minority group in the US habitual diet. Moreover, the study design will allow the assessment of dietary changes in an understudied population at increased cardiovascular risk due to the high prevalence of overweight and obesity. Collectively, these analyses will help identify the complex relationships of mango-derived nutrients and microbial metabolites to physiologic response.

Twenty-five (12-19 years of age) adolescents will be enrolled in a randomized, controlled 2-arm crossover dietary intervention trial. Participants will be randomized to consume either ¾ cups of mango or continue their habitual diet for 4 weeks, followed by a 4-week washout period before crossing over to the alternate group. The mango flesh will be cut into uniform chunks (2-3 cm) and portioned into individual servings that can be consumed either as-is or blended into a smoothie.

Being tested
Ataulfo mango
Keywords
mango, cardiometabolic, adolescents, microbiome
Medical subject headings
Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ataulfo mangoOther

    4 weeks of Ataulfo mango intake

Study groups in NCT07125001
Study groupRoleWhat they receive
Mango armExperimentalAtaulfo Mango intake
Receives: Other: Ataulfo mango
No mango intakeNo intervention4 weeks of no mango intake

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Microvascular Function

    Microvascular function as measured by peripheral arterial tonometry (ENDO PAT 2000)

    Measured: 4 weeks

Secondary outcomes (9)
  1. Cytokines

    Th17 cytokine panel

    Measured: 4 weeks

  2. short chain fatty acids

    both plasma and fecal

    Measured: 4 weeks

  3. Bile acids

    plasma bile acids

    Measured: 4 weeks

  4. zonulin

    serum zonulin

    Measured: 4 weeks

  5. soluble lipopolysaccharide binding protein

    plasma

    Measured: 4 weeks

  6. cd14

    plasma

    Measured: 4 weeks

  7. GLP-1

    fasting plasma levels

    Measured: 4 weeks

  8. plasma lipids

    total-, LDL-, HDL-cholesterol, and triglycerides

    Measured: 4 weeks

  9. IGF/IGFbp

    insulin like growth factor (IGF) and its associated binding proteins (BP)

    Measured: 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2025
  2. Study start1 Oct 2025
  3. Primary completion31 Mar 2028 (estimated)
  4. Study completion31 Mar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
25 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07125001
Sponsor's protocol ID
1939453
Status last verified
Jan 2026
First submitted
7 Jul 2025
Last updated
3 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Ataulfo mango in people with Cardiometabolic Health Indicators and Vascular Function in Healthy Volunteers, run by University of California, Davis at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Roberta R Holt, PhD (15304005952, rrholt@ucdavis.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Microvascular Function (time frame: 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in